Physician profile
Paul K Haynes
NPI 1386643211
$11,369.49
in general payments reported to CMS, 2019-2025
41 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $2,518 · 2021: $1,072 · 2022: $1,317 · 2023: $2,604 · 2024: $1,808 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,918.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,034.37 | 2019-2025 | |
| Allergan, INC. | $1,799.99 | 2020 | |
| Celgene Corporation | $843.56 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $755.66 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $741.27 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $710.04 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Daiichi Sankyo INC. | $435.49 | 2022-2024 | Injectafer |
| Redhill Biopharma INC. | $371.25 | 2020-2022 | |
| Pfizer INC. | $316.90 | 2019-2025 | |
| Gilead Sciences, INC. | $282.31 | 2019-2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $247.10 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $178.88 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $172.49 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $157.14 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $127.21 | 2021-2023 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,912.70 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.